Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | PTPRC | P08575 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5186572 | 0.80 | KMT2A (0.55) | SMN1; SMN2PTPRCMAPTCTSSCTSK | |
| SCHEMBL15674786 | 0.76 | MAPT (0.36) | SMN1; SMN2NPC1RAB9AHTTMAPT | |
| SCHEMBL15674785 | 0.76 | MAPT (0.36) | SMN1; SMN2NPC1RAB9AHTTMAPT | |
| SCHEMBL4152673 | 0.75 | TACR3 (0.40) | PTPRCCTSSCTSKTSHRCCR2 | |
| SCHEMBL15674964 | 0.74 | SMN1; SMN2 (0.37) | SMN1; SMN2NPC1RAB9APTPRCHTT | |
| SCHEMBL15675030 | 0.73 | NPC1 (0.39) | SMN1; SMN2NPC1RAB9APTPRCHTT | |
| SCHEMBL5185377 | 0.73 | SMN1; SMN2 (0.38) | SMN1; SMN2NPC1RAB9AHTTMAPT | |
| SCHEMBL17428951 | 0.72 | KMT2A (0.42) | HTTMAPTALDH1A1GAAATM | |
| SCHEMBL17525671 | 0.71 | ALDH1A1 (0.43) | SMN1; SMN2NPC1RAB9AHTTMAPT | |
| SCHEMBL5246965 | 0.71 | CTSS (0.48) | SMN1; SMN2PTPRCCTSSCTSKATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288549-B2 | Heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents | AVENTIS PHARMA S.A. (FR) | 2007-10-30 | — | — | US | disclosed |
| US-20050245505-A1 | Novel heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents | ENTASIS THERAPEUTICS LIMITED (GB) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245505-A1 | Novel heterocyclic compounds, method for preparing same and use thereof as medicines, in particular as antibacterial agents | FDPS, MRPL21, DHPS | SMN1; SMN2 4184/4885NPC1 2106/4885RAB9A 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.